Search Results

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator.

Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to Senti Bio.

ProJenX, Inc. announced the receipt of a $1M Hoffman ALS Clinical Trials Award from the ALS Association.

Broken String Biosciences announced it has entered a research collaboration with the Francis Crick Institute, a world-leading biomedical discovery institute dedicated to understanding the biology underlying health and disease.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results of COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), were presented at the 34th International Symposium on ALS/MND by Jeremy Shefner, M.D., Ph.D., Lead Investigator of COURAGE-ALS, Professor of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine Phoenix.